SCHEMBL5478309

SCHEMBL5478309

CC(=O)C=Cc1c(C)cccc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
IAPP P10997 2/20 0.48
MAPT P10636 3/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 3/20 0.43
PTGS1 P23219 1/20 0.41
HTT P42858 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RAF1 P04049 1/20 0.40
ABCB1 P08183 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
ALK Q9UM73 1/20 0.37
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5478305 1.00 GLA (0.52) GLATDP1IAPPMAPTLMNA
SCHEMBL23289048 0.84 ALDH1A1 (0.42) GLATDP1IAPPMAPTLMNA
SCHEMBL2059374 0.83 HCAR2 (0.50) ALDH1A1KMT2AKDM4ESMN1; SMN2GAA
SCHEMBL2059378 0.83 HCAR2 (0.50) ALDH1A1KMT2AKDM4ESMN1; SMN2GAA
SCHEMBL6049311 0.81 GLA (0.45) GLATDP1IAPPMAPTLMNA
SCHEMBL30560968 0.81 DRD2 (0.40) LMNAALDH1A1KDM4EPTGS1SMN1; SMN2
SCHEMBL6049312 0.81 GLA (0.45) GLATDP1IAPPMAPTLMNA
SCHEMBL5336688 0.78 ABCB1 (0.49) GLATDP1IAPPMAPTLMNA
SCHEMBL5336696 0.78 ABCB1 (0.49) GLATDP1IAPPMAPTLMNA
SCHEMBL3360246 0.78 IAPP (0.53) IAPPMAPTLMNAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070112015-A1 Substituted dihydropyridines and methods of use CHEMOCENTRYX, INC. (US) 2007-05-17 US disclosed
US-4826864-A Substituted imidazole derivatives useful as antihypertensive or antithromtic agent or divretic FARMOS GROUP LTD. (FI) 1989-05-02 US disclosed
US-4639464-A Antihypertensive substituted imidazole derivatives FARMOS GROUP, LTD. (FI) 1987-01-27 US disclosed
EP-0072615-B1 SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE Farmos Group Ltd. (FI) 1985-12-27 EP disclosed
US-4544664-A Antihypertensive substituted imidazole derivatives FARMOS GROUP, LTD. (FI) 1985-10-01 US disclosed
EP-0072615-A1 Substituted imidazole derivatives and their preparation and use Farmos Group Ltd. (FI) 1983-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112015-A1 Substituted dihydropyridines and methods of use C3AR1, C5AR1, C5AR2 GLA 2558/4885TDP1 3303/4885IAPP 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.